Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-08
2011-03-08
Maier, Leigh C (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07902159
ABSTRACT:
Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.
REFERENCES:
patent: 4436727 (1984-03-01), Ribi
patent: 4844894 (1989-07-01), Ribi
patent: 4866034 (1989-09-01), Ribi
patent: 4877611 (1989-10-01), Cantrell
patent: 4912094 (1990-03-01), Myers et al.
patent: 4987237 (1991-01-01), Myers et al.
patent: 5286718 (1994-02-01), Elliott
patent: 5653996 (1997-08-01), Hsu
patent: 5762943 (1998-06-01), Dolovich et al.
patent: 6013640 (2000-01-01), Elliott et al.
patent: 6113918 (2000-09-01), Johnson et al.
patent: 6303347 (2001-10-01), Johnson et al.
patent: 6355257 (2002-03-01), Johnson et al.
patent: 6399590 (2002-06-01), Elliott et al.
patent: 6525028 (2003-02-01), Johnson et al.
patent: 6638517 (2003-10-01), Reed et al.
patent: 7541020 (2009-06-01), Johnson et al.
patent: 2002/0009456 (2002-01-01), Crane
patent: 2002/0032165 (2002-03-01), Johnson et al.
patent: 2002/0048588 (2002-04-01), Johnson et al.
patent: 2003/0139356 (2003-07-01), Persing et al.
patent: 2003/0190333 (2003-10-01), Mossman et al.
patent: 2004/0147480 (2004-07-01), Persing et al.
patent: 2005/0227943 (2005-10-01), Johnson et al.
patent: 2 220 211 (1990-01-01), None
patent: WO 97/42947 (1997-11-01), None
patent: WO 98/50399 (1998-11-01), None
patent: WO 01/10221 (2001-02-01), None
patent: WO 01/34617 (2001-05-01), None
patent: WO 01/34794 (2001-05-01), None
patent: WO 01/70209 (2001-09-01), None
Chase, J. et al., “Effect of monophosphoryl lipid A on host resistance to bacterial infection,”Infection and Immunity, vol. 53(3), pp. 711-712 (Sep. 1986).
Gustafson, G.L., et al., “Monophosphoryl lipid as a prophylactic for sepsis and septic shock,”Bacterial Endotoxins: Lipopolysaccharides, vol. 392, pp. 567-579 (1995).
Ogawa, T., et al., “Immunopharmacological activities of the nontoxic monophosphoryl lipid A ofPorphyromonas gingivalis,” Vaccine, vol. 14(1), pp. 70-76 (1996).
Johnson et al., “3-O-desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities,”J. Med. Chem. 42:4640-4649, 1999.
Kirschning et al., “Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide,”J. Exp. Med. 188(11):2091-2097, Dec. 7, 1998.
Poltorak et al., “Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations inTlr4gene,”Science282:2085-2088, Dec. 11, 1998.
Qureshi et al., “Endotoxin-tolerant mice have mutations in toll-like receptor 4 (Tlr4),”J. Exp. Med. 189(4):615-625, Feb. 15, 1999.
Ulrich and Meyers, inVaccine Design: The Subunit and Adjuvant Approach: Powell and Newman Eds.; Plenum: New York, 495-524, 1995.
Yang et al., “Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signaling,”Nature 395:284-288, Sep. 17, 1998.
Alderson, Mark R. et al.; “TLR4 agonists as immunomodulatory agents”; 2006,Endotoxin Research,vol. 12, pp. 313-319.
Baldridge, Jory et al.; “Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529”; 2002,J. Endotoxin Res., vol. 8, pp. 453-458.
Baldridge, Jory et al.; “Monophosphoryl Lipid A and Synthetic Lipid A Mimetics As TLR4-Based Adjuvants and Immunomodulators”; 2003,Immunological and Clinical Principles, pp. 235-255.
Baldridge, Jory et al.; “Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents”; 2004,Expert Opin. Bio. Ther., vol. 4, No. 7, pp. 1129-1138.
Casale, Thomas B. et al.; “Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis”; 2006,Ann Allergy Asthma Immunol., vol. 97, pp. 454-456.
Check, William; “Innate Immunity Depends on Toll-Like Receptors”; 2004,ASM News, vol. 70, No. 7, pp. 317-322.
Cluff, Christopher W. et al.; “Synthetic Toll-Like Receptor 4 Agonists Stimulate Innate Resistance to Infectious Challenge”; 2005,Infection and Immunity, vol. 73, No. 5, pp. 3044-3052.
Fang, F.; “Mechanisms of nitric oxide- related antimicrobial activity”; 1999,J. Clin. Invest., vol. 99, No. 12, pp. 2818-2825.
Fort, Madeline M. et al.; “A Synthetic TLR4 Antagonist Has Anti-Inflammatory Effects in Two Murine Models of Inflammatory Bowel Disease”; 2005,The Journal of Immunology, vol. 174, pp. 6416-6423.
Gustafson and Rhodes, “A Rationale for the Prophylactic Use of Monophosphoryl Lipid A in Sepsis and Septic Shock,”Biochemical and Biophysical Research Communications, vol. 182, No. 1, pp. 269-275 (1992).
Hovde, Carolyn J. et al.; “APGs (Lipid A mimetics) for protection against pulmonary plague”; 2007, Presentation from the 5th Annual ASM Biodefense and Emerging Infectious Diseases Research Meeting, 34 pages.
Ismaili, Jamila et al.; “Monophosphoryl Lipid A Activates Both Human Dendritic Cells and T Cells”; 2002,J. Immunology, vol. 168, pp. 926-932.
Luxameechanporn, Thongchai et al.; “Evaluation of Importance of Toll-like Receptor 4 in AcuteStreptococcus pneumoniaeSinusitis in Mice”; 2005,Arch Otolaryngol Head Neck Surgery, vol. 131, pp. 1001-1006.
Persing, David H. et al.; “Taking toll: lipid A mimetics as adjuvants and immunomodulators”; 2002,Trends in Microbiology, vol. 10, No. 10, pp. S32-S37.
Persing, David H. et al.; “Toll-like receptor 4 agonists as vaccine adjuvants”; 2006,Immunopotentiators in Modern Vaccines, pp. 93-107.
Quesniaix et al., “Toll-Like Receptors: emerging targets of immunomodulation”,Exp. Opin. Ther. Pat.(2004) vol. 14, pp. 85-100.
Stover, Axel G. et al.; “Structure-Activity Relationship of Synthetic Toll-like Receptor 4 Agonists”; 2004,The Journal of Biological Chemistry, vol. 279, No. 6, pp. 4440-4449.
Tiberio, Lorrie et al.; “Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A”; 2004,Vaccine, vol. 22, pp. 1515-1523.
Wang, J. et al'; “Macrophages are a significant source of type 1 cytokines during mycobacterial infection”; 1999,J. Clin. Invest., vol. 103, No. 7, pp. 1023-1029.
Baldridge Jory R.
Crane Richard Thomas
Elliot Gary T.
Johnson David A.
Lacy Michael J.
Corixa Corporation
Kilpatrick Towsend & Stockton LLP
Maier Leigh C
LandOfFree
Prophylactic and therapeutic treatment of infectious and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prophylactic and therapeutic treatment of infectious and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prophylactic and therapeutic treatment of infectious and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2768631